Cargando…

Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer

Immune-checkpoint inhibitors (ICI) targeting programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) have quickly changed the treatment landscape in advanced non-small cell lung cancer. However, any patient treated with an immune checkpoint inhibitor is at risk for immune-related adverse events (irA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yao, Wang, Yimeng, Yu, Jinming, Meng, Xiangjiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520566/ https://www.ncbi.nlm.nih.gov/pubmed/36189237 http://dx.doi.org/10.3389/fimmu.2022.998516

Ejemplares similares

Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy
por: Zhou, Shujie, et al.
Publicado: (2022)

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
por: Jiang, Mengjie, et al.
Publicado: (2023)

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
por: Liu, Yang, et al.
Publicado: (2018)

Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
por: Chen, Yu, et al.
Publicado: (2020)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
por: Chen, Yu, et al.
Publicado: (2021)

Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors
por: Eckert, Franziska, et al.
Publicado: (2019)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review
por: Xu, Tongzhen, et al.
Publicado: (2022)

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
por: Johansen, Astrid Z., et al.
Publicado: (2023)

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation
por: Ma, Lin, et al.
Publicado: (2021)

Corrigendum: Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review
por: Xu, Tongzhen, et al.
Publicado: (2023)

Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy
por: Liao, Xiu-Yong, et al.
Publicado: (2019)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
por: Xu, Chao, et al.
Publicado: (2023)

The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment
por: Shi, Ming-Yan, et al.
Publicado: (2023)

Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors
por: Yang, Ximing, et al.
Publicado: (2022)

Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
por: Chen, Yu, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience
por: Bai, Menglin, et al.
Publicado: (2022)

Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2023)

Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma
por: Xiao, Linlin, et al.
Publicado: (2022)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
por: Li, Butuo, et al.
Publicado: (2021)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
por: Su, Qiang, et al.
Publicado: (2019)

A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab
por: Gao, Rongmao, et al.
Publicado: (2023)

Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?
por: Chen, Dawei, et al.
Publicado: (2018)

Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer
por: Jin, Peng, et al.
Publicado: (2022)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
por: Song, Yuxiao, et al.
Publicado: (2020)

Corrigendum: Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?
por: Chen, Dawei, et al.
Publicado: (2021)

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
por: Grasselly, Chloé, et al.
Publicado: (2018)

Radiotherapy and checkpoint inhibitors: a winning new combination?
por: Ko, Eric C., et al.
Publicado: (2018)

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
por: Chen, Yu, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer
por: Shao, Taihang, et al.
Publicado: (2022)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment
por: Hassanian, Hamidreza, et al.
Publicado: (2022)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lig8gdfpiu1f2h52bnpk3ir4ep